Apr 08, 2022 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 05, 2022 4:01 pm EDT Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
Apr 04, 2022 4:01 pm EDT Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
Mar 04, 2022 4:01 pm EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Mar 02, 2022 8:00 am EST Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 42nd Annual Virtual Healthcare Conference
Feb 28, 2022 4:05 pm EST Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
Feb 17, 2022 4:01 pm EST Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
Feb 07, 2022 4:01 pm EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)